A porous silica particles according to an embodiment of the present disclosure includes a plurality of pores with a diameter of 5 nm to 100 nm. The porous silica particles have particular physical properties, can deliver all various drugs by a supported amount in a sustained manner, and can be parenterally administered.

The provision of technology for reducing the unpleasant taste of ibuprofen in ibuprofen-containing oral pharmaceutical formulations. An oral pharmaceutical formulation in which the unpleasant taste of ibuprofen is reduced, which contains (A) ibuprofen or salt thereof or solvate of these, and (B) magnesium oxide, wherein the mass ratio [(B)/(A)] of component (A) and component (B) is 0.2-1.5.

Provided herein are pharmaceutical compositions for treating human lung diseases comprising a stabilized DNase I polypeptide containing a non-standard amino acid, a functional fragment thereof, or a variant thereof that maintains enzymatic activity even under harsh conditions, such as reducing environments. The present disclosure also relates to methods of using the composition for the treatment of human of lung diseases or for the disruption of biofilms.

The present application provides methods and processes for making and using a lyophilized mesenchymal stem cell secretome, as well as methods for treating ocular conditions and/disorders with the reconstituted lyophilized mesenchymal stem cell secretome described herein.

6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt, amorphous form, polymorph form, or pharmaceutical composition (including solid formulations or liquid formulations) thereof and the use thereof for treating diseases and disorders which can be treated with a RET kinase inhibitor, such as RET-associated diseases and disorders, e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors, and gastrointestinal disorders such as IBS are disclosed.

The present invention relates to empty porous particles having a diameter between 0.1 and 1000 μm, as measured by e.g. SEM, for use in diagnosis, prevention and/or postponement of neurodegenerative diseases, or for prevention and/or postponement of degeneration of neurons and glia. The invention also relates to a method of identifying biomarkers for use in diagnosis.

Provided herein are dynamic clusters of atom particles activated in extracellular fluid intended to reverse the accumulation of advanced glycation end products which are closely related to chronic diseases. The manufacturing process involves material preparation, particle fragmentation, pH adjustment, selection of atom particles and construction of dynamic clusters through electro-magnetic field and flow velocity adjustment, and separation of dynamic clusters from the liquid. The dynamic clusters of atom particles deal with advanced glycation end products, which are diverse in chemical nature, by responding to irregularities in the electromagnetic field disrupted by highly reactive free radicals advanced glycation end products emit. Such mechanism makes it possible to extend the applications to diseases related to irregular free radical activities other than chronic diseases like in HIV replication or neural signalling.

A method is described for producing a dosage form and granules including surface-reacted calcium carbonate. Also described, are tablets and/or capsules obtained by the method. Methods using such a surface-reacted calcium carbonate, and a dosage form comprising the granules are also described. Further, methods of using the granules, or the tablets and/or capsules, or the dosage form in a pharmaceutical product, a nutraceutical product, an agricultural product, a cosmetic product, a home product, a food product, a packaging product and a personal care product are also described. A pharmaceutical product, a nutraceutical product, an agricultural product, a cosmetic product, a home product, a food product, a packaging product and a personal care product including the granules, or the tablets and/or capsules, or the dosage form are also described.

The present invention relates to methods of treating an auditory disorder. In particular, the present invention relates to treating an auditory disorder using supraparticles comprising a therapeutic payload.

The present disclosure concerns effervescent compositions and methods of making and using the same. In some embodiments, the disclosed effervescent compositions are formed from an input blend comprising an acid and a base by granulating the input blend in a twin-screw processor. The granules formed from the input blend can be formed by an in situ granulating agent, which can be a portion of the acid that melts during granulation. In some embodiments, the effervescent compositions can be made using a twin-screw processor comprising an intake zone for receiving an input blend comprising an acid and a base; a granulation initiation zone for melting only a portion of the acid to serve as an in situ granulating agent; a granulation completion zone for granulating the input blend; and an outlet for discharging the granules.